Inflammation fuels one of the most aggressive forms of lung cancer

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to chemotherapy.

AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its experimental drug ceralasertib failed to improve the overall survival of patients with advanced lung cancer.
ZME Science on MSN

When Lung Cancer Fears Emerged in the 1950s, Kent Put a Filter on their Cigarettes. It Was Made From Asbestos

Bolivian crocidolite was used in approximately 13 billion Kent Micronite cigarette filters, manufactured from March 1952 until May 1956. Beyond the individual risks of tobacco smoke and asbestos fibers, the two carcinogens work together in a deadly synergy, creating a risk far greater than the sum of their parts.

FDA approves first subcutaneous drug for EGFR-mutated non-small cell lung cancer

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).